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Abstract
Introduction: Although inhalation of 80 parts per million (ppm) of hydrogen sulfide (H2S) reduces metabolism in
mice, doses higher than 200 ppm of H2S were required to depress metabolism in rats. We therefore hypothesized
that higher concentrations of H2S are required to reduce metabolism in larger mammals and humans. To avoid the
potential pulmonary toxicity of H2S inhalation at high concentrations, we investigated whether administering H2S
via ventilation of an extracorporeal membrane lung (ECML) would provide means to manipulate the metabolic rate
in sheep.
Methods: A partial venoarterial cardiopulmonary bypass was established in anesthetized, ventilated (fraction of
inspired oxygen = 0.5) sheep. The ECML was alternately ventilated with air or air containing 100, 200, or 300 ppm
H2S for intervals of 1 hour. Metabolic rate was estimated on the basis of total CO2 production ( VCO2 ) and O2
consumption ( VO2 ). Continuous hemodynamic monitoring was performed via indwelling femoral and pulmonary
artery catheters.
Results: VCO2 , VO2 , and cardiac output ranged within normal physiological limits when the ECML was
ventilated with air and did not change after administration of up to 300 ppm H2S. Administration of 100, 200 and
300 ppm H2S increased pulmonary vascular resistance by 46, 52 and 141 dyn·s/cm
5, respectively (all P ≤ 0.05 for air
vs. 100, 200 and 300 ppm H2S, respectively), and mean pulmonary artery pressure by 4 mmHg (P ≤ 0.05), 3 mmHg
(n.s.) and 11 mmHg (P ≤ 0.05), respectively, without changing pulmonary capillary wedge pressure or cardiac
output. Exposure to 300 ppm H2S decreased systemic vascular resistance from 1,561 ± 553 to 870 ± 138 dyn·s/cm
5
(P ≤ 0.05) and mean arterial pressure from 121 ± 15 mmHg to 66 ± 11 mmHg (P ≤ 0.05). In addition, exposure to
300 ppm H2S impaired arterial oxygenation (PaO2 114 ± 36 mmHg with air vs. 83 ± 23 mmHg with H2S; P ≤ 0.05).
Conclusions: Administration of up to 300 ppm H2S via ventilation of an extracorporeal membrane lung does not
reduce VCO2 and VO2 , but causes dose-dependent pulmonary vasoconstriction and systemic vasodilation. These
results suggest that administration of high concentrations of H2S in venoarterial cardiopulmonary bypass circulation
does not reduce metabolism in anesthetized sheep but confers systemic and pulmonary vasomotor effects.
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Introduction
Balancing cellular oxygen supply and demand is a key
therapeutic approach to protecting organs such as the
brain, kidneys and heart from ischemic injury. Permis-
sive hypothermia and active cooling have been shown to
reduce oxygen demands in patients experiencing stroke,
cardiac arrest, cardiac surgery, severe trauma and other
instances of ischemia and subsequent reperfusion [1-4].
However, hypothermic reduction of aerobic metabolism
has been associated with adverse effects, including
increased rates of infection and coagulopathy [5,6].
Developing other methods to acutely reduce metabolism
in patients could be clinically useful.
Hydrogen sulfide (H2S) is an inhibitor of cytochrome
C oxidase in the mitochondrial electron transport chain
[7] that reduces metabolism and body temperature in
mice and rats [8,9]. Inhalation of H2S or intravenous
administration of H2S donor compounds (NaHS or
Na2S) can protect rodents from hypoxia [10] or hemor-
rhagic shock [11], improve survival rates after cardiac
arrest and cardiopulmonary resuscitation in mice [12],
and attenuate myocardial ischemia-reperfusion injury in
both rodents [13] and pigs [14].
Although inhaling H2S at 60 to 80 ppm reduces meta-
bolism in mice, it has been reported that inhaled H2S
does not depress total CO2 production ( VCO2 ) and
total O2 consumption ( VO2 ) in sedated, spontaneously
breathing sheep (60 ppm H2S) [15] or anesthetized, ven-
tilated piglets (20 to 80 ppm H2S) [16]. On the other
hand, Struve et al. [8] reported that inhalation of H2S at
200 to 400 ppm, but not at 30 to 80 ppm, decreased
body temperature in rats. Similarly, Morrison et al. [11]
showed that inhaling H2S at 300 ppm was required to
decrease VCO2 in rats, in contrast to 80 ppm in mice.
While these observations suggest that higher levels of
H2S are likely to be required to alter metabolic rates in
larger animals [11], the effects of higher concentrations
of H2S on metabolism in larger mammals have not been
examined.
It is well documented, however, that inhalation of high
concentrations of H2S may injure the bronchial mucosa,
cause pulmonary edema, and impair gas exchange
[17,18]. To examine the impact of delivering higher con-
centrations of H2S to the body without incurring the
pulmonary toxicity of H2S inhalation, we administered
H2S gas via an extracorporeal membrane lung (ECML).
We hypothesized that high concentrations of H2S deliv-
ered via ECML in a partial venoarterial bypass system
delivering blood to the aortic root might reduce the
metabolic rate in sheep at rest. If ECML ventilation with
H2S was found to reduce the metabolic rate in sheep,
this method might provide a novel approach to balance
the supply and demand of oxygen in a variety of
situations, including in those patients who are supported
by extracorporeal circulation during cardiac surgery or
severe acute respiratory distress.
Materials and methods
All procedures described here were approved by the
Subcommittee on Research Animal Care of the Massa-
chusetts General Hospital, Boston, MA, USA, and
adhered to the principles of the Declaration of Helsinki
and the Recommendations for the Care and Use of
Animals.
Animal housing and maintenance
Five female purebred Polypay sheep (body weight: 30.6
± 2.5 kg, mean ± SD) were obtained from a single-
source breeder (New England Ovis LLC, Rollinsford,
NH, USA) and were housed under standard environ-
mental conditions (air-conditioned room at 22°C, 50%
relative humidity, 12-hour light-dark cycle) for at least 5
days prior to each study. Animals were fed standard
chow (Rumilab diet 5508; PMI Feeds Inc., St. Louis,
MO, USA) twice daily and were fasted for 24 hours
with free access to water before each experiment.
Instrumentation
After intramuscular premedication with 5 mg/kg keta-
mine (ketamine hydrochloride; Hospira Inc., Lake For-
est, IL, USA) and 0.1 mg/kg xylazine (Anased; Lloyd
Laboratories, Shenandoah, IA, USA), a venous cannula
(Surflo IV catheter 18G; Terumo, Elkton, MD, USA)
was inserted into an ear vein and a bolus of 0.1 to 0.2
mg/kg diazepam (Diazepam USP; Hospira, Lake Forest,
IL, USA) administered intravenously (iv). Subsequently,
the animals were placed in a supine position and were
intubated and mechanically ventilated with a volume-
controlled mode (fraction of inspired oxygen (FiO2)
50%, tidal volume 10 ml/kg) (7200 Series Ventilator Sys-
tem; Puritan Bennett, Boulder, CO, USA). Anesthesia
was maintained by a constant rate infusion of ketamine
at 3 mg∙kg-1∙h-1 and diazepam at 0.5 mg∙kg-1∙h-1.
Respiratory rate was adjusted to maintain the end-tidal
CO2 between 35 and 40 mmHg. An arterial catheter
(18G, FA-04018; Arrow Inc., Reading, PA, USA) was
placed into the right femoral artery via percutaneous
puncture to monitor mean arterial pressure (MAP) and
to sample blood. Subsequently, an 8-Fr heptalumen pul-
monary artery catheter (746HF8; Edwards Lifesciences,
Irvine, CA, USA) was introduced through a percuta-
neous sheath (9 Fr, PB-09903; Arrow Inc., Reading, PA,
USA) into the left external jugular vein for blood sam-
pling and monitoring of mean pulmonary artery pres-
sure (MPAP), central venous pressure (CVP), pulmonary
capillary wedge pressure (PCWP), continuous cardiac
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output (CO) and blood temperature. Finally, a transure-
thral bladder catheter and a transesophageal gastric tube
were inserted to drain urine and gastric secretions. Dur-
ing the first hour after induction, animals received an
infusion of 500 ml of 6% hetastarch (Hextend; Hospira,
Lake Forest, IL, USA) and 500 ml of lactated Ringer’s
solution (Baxter, Deerfield, IL, USA); thereafter, 16
ml∙kg-1∙h-1 of lactated Ringer’s solution and 9 ml∙kg-1∙h-1
of 0.9% saline were infused to match fluid losses from
diuresis and gastric secretions.
Extracorporeal circulation
A 20-Fr single-stage venous cannula (DLP; Medtronic,
Minneapolis, MN, USA) and a 14-Fr arterial cannula
(Fem-Flex II; Medtronic) were surgically inserted and
advanced through the right external jugular vein and
right common carotid artery, respectively, thereby
enabling blood withdrawal from the superior vena cava
and arterial blood return to the aortic root from the
extracorporeal cardiopulmonary bypass circuit. The
bypass circuit comprised a three-eighths-inch polyethy-
lene tubing line (3506; Medtronic), an occlusive roller
pump (Cardiovascular Instruments Corp., Wakefield,
MA, USA) and an ECML (Trillium 541TT Affinity;
Medtronic) with an integral heat exchanger, and it was
primed with a total extracorporeal priming volume of
500 ml of 0.9% saline. A bolus injection of unfractio-
nated heparin (200 IU/kg heparin sodium; APP Pharma-
ceuticals, LLC, Schaumburg, IL, USA) prior to
cannulation, followed by a continuous infusion of 200
IU/kg unfractionated heparin per hour was used for
anticoagulation. A thermostat-controlled water bath
(Haake DC10-P5; Thermo Scientific, Waltham, MA,
USA) supplying the heat exchanger with circulating
water was maintained at 38°C. The gas compartment of
the oxygenator was ventilated at a constant flow of 5 l/
min with oxygen, air and H2S (10,000 ppm hydrogen
sulfide balanced with nitrogen; Airgas Specialty Gases,
Port Allen, LA, USA) blended to achieve an oxygen con-
centration of 21% with 0, 100, 200, or 300 ppm H2S.
A handheld iTX Multi-Gas detector (1 ppm detection
threshold; Industrial Scientific, Oakdale, PA, USA) was
used to monitor the H2S concentrations at the inlet and
outlet of the gas compartment.
Experimental procedures
Once partial venoarterial bypass perfusion was started,
the transmembrane blood flow was gradually increased
to 1 l/min. Then the respiratory rate was reduced to
maintain an end-tidal partial pressure of CO2 of 35 to
40 mmHg, and sheep were paralyzed (0.1 mg∙kg-1∙h-1 of
pancuronium bromide iv; Sicor Pharmaceuticals, Irvine,
CA, USA) to prevent spontaneous respiratory activity,
asynchronous ventilation and excessive skeletal muscle
O2 consumption. A 1-hour equilibration period was
allowed to achieve hemodynamic stability before base-
line measurements were taken.
During the following 6 hours, the ECML gas compart-
ment was alternately ventilated with either air or air
plus H2S for 1-hour intervals, thereby administering
0 ppm H2S during the first hour, 100 ppm H2S during
the second hour, followed by 0 and 200 ppm during the
third and fourth hours and finally 0 and 300 ppm H2S
during the fifth and sixth hours. This procedure was
chosen to detect the hemodynamic and metabolic effects
of exposure to increasing H2S concentrations through
the membrane lung, as well as their reversibility.
Measurements and monitoring
A digital data acquisition system (PowerLab and Chart
software version 5.0; ADInstruments, Colorado Springs,
CO, USA) was used to continuously record MAP,
CVP and MPAP. A Vigilance II Monitor (Edwards Life-
sciences) was used to continuously measure CO and cen-
tral blood temperature. End-tidal CO2, as well as the
total amount of CO2 exhaled from the biological lungs
per unit of time ( V COL 2 ), was measured by an in-
stream, noninvasive, continuous monitoring device
(NICO Cardiopulmonary Management System; Philips
Respironics, Murrysville, PA, USA). Blood gas tensions,
hemoglobin concentrations, and acid-base balances were
determined in arterial and mixed venous blood samples
using a standard blood gas analyzer (ABL 800 Flex;
Radiometer, Copenhagen, Denmark).
Plasma concentrations of H2S were measured in dupli-
cate as total sulfide concentrations using the methylene
blue formation method with modifications [19]. Briefly,
arterial and ECML-efferent blood was sampled and
immediately centrifuged at 4°C to obtain plasma. An ali-
quot of plasma (100 μl) was added with 2% zinc acetate
(200 μl) to trap the H2S, and 10% trichloroacetic acid
(200 μl) was added to precipitate plasma proteins,
immediately followed by 20 mM N,N-dimethyl-1,4-phe-
nylenediamine sulfate in 7.2 M HCl (100 μl) and 30
mM FeCl3 in 1.2 M HCl (100 μl). The reaction mixture
was incubated for 20 minutes at room temperature and
centrifuged at 14,000 rpm for 10 minutes. The absor-
bance of the supernatant was measured at 670 nm using
a spectrophotometer. Total sulfide concentration was
calculated against a standard curve made with known
concentrations of Na2S solutions in phosphate-buffered
saline. The lower detection limit of this assay was
approximately 1 μM sulfide in plasma.
Calculation of carbon dioxide production
Total VCO2 was monitored continuously and was
calculated as the sum of CO2 exhaled from the lungs
per unit of time ( V COL 2 ) and the amount of CO2
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removed from the circulation via the membrane oxyge-
nator ( V COM 2 ), according to the following equations:
 V CO V COL 2 E E 2  F , (1)
where VE is the expiratory minute volume and FECO2
is the mean fraction of CO2 in expired air. Quantifica-
tion of VE and FECO2 and the calculation of V COL 2
were accomplished by a continuous noninvasive NICO
device (see ‘Measurements and monitoring’ section):
V CO Q COM 2 gas M 2  F , (2)
where Qgas is the total gas flow exhausted from the
membrane oxygenator and FECO2 is the fraction of CO2
in the exhaust gas. Qgas was continuously monitored by
a microturbine flow meter (S-113 Flo-Meter; McMillan
Co., Georgetown, TX, USA), and FECO2 was measured
by a sidestream infrared CO2 analyzer (WMA-4; PP-Sys-
tems, Amesbury, MA, USA).
Calculation of oxygen consumption
Total VO2 was calculated on the basis of blood samples
drawn 10 minutes before the end of each period of
exposure to air or H2S as follows:
VO (c O -c O ) Q -(c O -c O ) Q2 a 2 v 2 L e 2 a 2 M   , (3)
where caO2 is the oxygen content of arterial blood,
cvO2 is the oxygen content of mixed venous blood, QL
is transpulmonary blood flow (here meaning continuous
CO measured via pulmonary artery catheter), ceO2 is
the oxygen content of ECML-efferent blood and QM is
extrapulmonary blood flow (here meaning transmem-
brane blood flow). Blood oxygen content (cO2) was cal-
culated according to the following general equation:
cO [Hb] O Hb 1.34 pO 0.0032 2 2    F , (4)
where [Hb] is the hemoglobin concentration, FO2Hb
is the fraction of oxyhemoglobin, 1.34 is Hüfner’s con-
stant and pO2 is the oxygen tension.
Statistical analysis
Statistical analysis was performed using the SPSS 14.0
data package for Windows (SPSS, Chicago, IL, USA)
and GraphPad Prism version 5.02 software (GraphPad
Software, La Jolla, CA, USA). All data are reported as
means ± SD unless indicated otherwise. Hemodynamic
parameters, VCO2 and body temperature were mea-
sured continuously and are reported as the mean value
derived from the last 10 minutes of each period of expo-
sure to air or H2S. In addition, hemodynamic para-
meters were averaged every 5 minutes for a time course
analysis, and these data are displayed in Figures 1 and 2.
Blood gas tension analysis, determination of blood
hemoglobin concentrations and quantification of H2S
plasma concentrations required blood sampling. Samples
were obtained during the last 5 minutes of each period
of exposure. Depending on the distribution of the data
as determined using the Shapiro-Wilk test for normal
distribution, either Student’s t-test or the Wilcoxon
signed-rank test was performed to compare each H2S
ventilation period with the respective baseline period (0
ppm H2S). Statistical significance was assumed at P ≤
0.05. On the basis of data derived from pilot experi-
ments, power and sample size calculations were per-
formed using PS: Power and Sample Size Calculation
version 2.1.31 software by Dupont and Plummer [20].
Results
Metabolic effects of H2S administration
The baseline VCO2 value was stably near approximately
3.4 ml∙kg-1∙min-1 when the ECML was ventilated with
air. Direct diffusion of H2S into blood via the ECML at
100, 200 or 300 ppm did not alter VCO2 (Figure 3) orVO2 (Figure 4). The temperature of the ECML heat
exchanger water bath was kept at 38°C and resulted in a
constant central blood temperature of 37.4 ± 0.4°C
throughout the experiment (Table 1).
Hemodynamic effects of H2S administration
After 1 hour of exposure to either 100 or 200 ppm H2S
via ECML ventilation and partial venoarterial perfusion,
MAP was not different from baseline. However, expo-
sure to 300 ppm H2S for 1 hour decreased MAP from
121 ± 15 mmHg to 66 ± 11 mmHg and reduced
Figure 1 Systemic vascular hemodynamics. Systemic vascular
hemodynamics in five sheep challenged with alternate exposure to
hydrogen sulfide (H2S) (gray bars) by ventilation of an
extracorporeal membrane lung with 0 or 100 ppm H2S in air, 200
ppm H2S in air and 300 ppm H2S in air for 1-hour intervals each.
Data are presented as means ± standard error of the mean. MAP,
mean arterial pressure; CO, cardiac output; SVR, systemic vascular
resistance; ppm, parts per million.
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systemic vascular resistance (SVR) from 1561 ± 553
dyn·s/cm5 to 870 ± 138 dyn·s/cm5 (Table 1). We noted
that MAP increased transiently during exposure to 100
and 200 ppm H2S (Figure 1) and that this increase was
rapidly reversed upon application of air without added
H2S. Subsequently, exposure to 300 ppm H2S induced a
biphasic systemic pressor response characterized by
increased MAP and SVR during the first 20 minutes of
H2S exposure followed by a rapid decrease of MAP and
pronounced irreversible hypotension (Figure 1).
MPAP and pulmonary vascular resistance (PVR)
increased in response to H2S exposure, with the greatest
increase (ΔMPAP, approximately 10 mmHg; ΔPVR,
+51%) observed in response to 300 ppm H2S (Table 1).
Time course analysis (Figure 2) suggested that PVR
increased after exposure to 100, 200 and 300 ppm H2S
in a reversible, dose-dependent manner. Heart rate and
CO did not change in response to H2S exposure.
Pulmonary gas exchange and acid-base status
Arterial CO2 tension levels were within physiological lim-
its throughout the experiment and did not change in
response to H2S. Mixed venous CO2 tension (PvCO2)
ranged between 35 and 41 mmHg and did not change in
response to H2S. While arterial oxygenation (PaO2) was
not significantly affected by 100 or 200 ppm H2S, PaO2
decreased from 114 ± 36 to 83 ± 23 mmHg (P ≤ 0.05)
upon administration of 300 ppm H2S. Arterial oxygen
tension did not recover during the subsequent interval of
air exposure without H2S. Mixed venous O2 tension ran-
ged between 50 and 56 mmHg, and there was no relevant
change upon H2S administration. While arterial pH (pHa)
was within physiological limits throughout the experi-
ment, significant metabolic acidosis was observed during
exposure to 300 ppm H2S, with concomitant changes in
mixed venous pH. Arterial hemoglobin concentrations
were near 9 g/dl throughout the experiment. Exposure to
200 ppm H2S transiently increased hemoglobin concen-
trations by 2 ± 0 g/dl (Table 1).
Total plasma sulfide concentrations
Plasma sulfide concentrations were determined in dupli-
cate from arterial and ECML-efferent blood. The base-
line plasma concentration of sulfide was 1.9 ± 0.3 μM,
and this value was only slightly higher than the lower
detection limit (approximately 1 μM) for this assay.
Ventilation of ECML with air did not affect plasma
Figure 2 Pulmonary vascular hemodynamics. Pulmonary vascular
hemodynamics in five sheep challenged with alternate exposure to
hydrogen sulfide (H2S) (gray bars) by ventilation of an
extracorporeal membrane lung with 0 or 100 ppm H2S in air, 200
ppm H2S in air and 300 ppm H2S in air for 1-hour intervals each.
Data are presented as means ± standard error of the mean. MPAP,
mean pulmonary artery pressure; CO, cardiac output; PVR,
pulmonary vascular resistance; ppm, parts per million.
Figure 3 Carbon dioxide production during administration of
hydrogen sulfide (H2S). Total carbon dioxide production ( VCO2 )
in five sheep challenged with alternate exposure to H2S by
ventilation of an extracorporeal membrane lung with 0 or 100 ppm
H2S in air, 200 ppm H2S in air and 300 ppm H2S in air for 1-hour
intervals each. Values are derived from the last 10 minutes of each
period of exposure to air or H2S and are presented as means ±
standard error of the mean. ppm, parts per million; n.s. = P > 0.05.
Figure 4 Oxygen consumption during administration of
hydrogen sulfide (H2S). Total carbon dioxide production ( VO2 )
in five sheep challenged with alternate exposure to H2S by
ventilation of an extracorporeal membrane lung with 0 or 100 ppm
H2S in air, 200 ppm H2S in air and 300 ppm H2S in air for 1-hour
intervals each. Values are derived from blood samples taken during
the last 10 minutes of each period of exposure to air or H2S and are
presented as means ± standard error of the mean. ppm, parts per
million; n.s. = P > 0.05.
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sulfide concentrations in the efferent blood of the
ECML. In ECML-efferent blood, plasma sulfide concen-
tration increased to 7 ± 6, 27 ± 6 and 62 ± 12 μM/l
during ECML ventilation with 100, 200 and 300 ppm
H2S, respectively. However, no sulfide was detected in
plasma samples of blood collected from the femoral
artery during exposure to 100, 200 or 300 ppm H2S.
Discussion
The results of the present study reveal that ventilating
an ECML with up to 300 ppm H2S in venoarterial car-
diac bypass circulation does not reduce whole body CO2
production or O2 consumption in anesthetized sheep. In
addition, we have demonstrated that administration of
300 ppm H2S via ECML ventilation causes significant
adverse effects, including pulmonary vasoconstriction,
systemic vasodilation and hypoxemia. The current
results do not support the hypothesis that high concen-
trations of H2S delivered via an ECML can reduce the
metabolic rate in large mammals at rest.
In an attempt to bypass the direct pulmonary toxicity of
inhaled H2S, we used an ECML to directly diffuse high
concentrations of H2S gas into the blood. The absence of
H2S (lower limit of detection 1 ppm) in the gas outlet of
the artificial lung during ventilation with up to 300 ppm
H2S indicates that H2S is highly diffusible into blood
through the membrane and that a single passage is suffi-
cient for complete uptake of the gas. Thus, assuming com-
plete uptake of H2S during ventilation of the ECML at a
gas flow of 5 l/min with 300 ppm H2S (at standard condi-
tions for temperature and pressure), a total amount of 1.5
ml of H2S (that is, approximately 67 μM) are administered
via the membrane every minute. This sums to about 134
μM H2S/kg per hour delivered to a 30-kg sheep in the cur-
rent study. In contrast, the total amount of H2S adminis-
tered in previous studies in sheep [15] and pigs [16] were
approximately 13 μM/kg/h and approximately 42 μM/kg/
h, respectively, assuming complete uptake of H2S from the
alveolar space and an alveolar ventilation of 6 l/min in a
74-kg sheep, and 1.2 l/min in a 6-kg pig. Therefore, the
systemic dose of H2S supplied in the present study was
about three times greater than that applied in pigs and 10
times greater than the dose applied in sheep. If any of the
alveolar H2S were exhaled, the ratio of the uptake via the
membrane artificial lung in the present study and the
uptake via the natural lungs in previous reports would be
even greater. Nonetheless, our measurements suggest that
administration of H2S up to 134 μM/kg/h does not reduceVCO2 or VO2 in sheep.
Table 1 Hemodynamics and blood gas dataa
Parameter 0 ppm 100 ppm 0 ppm 200 ppm 0 ppm 300 ppm
Hemodynamics, means ± SD
HR, beats/min 139 ± 24 148 ± 29 154 ± 5 172 ± 28 165 ± 28 150 ± 31
MAP, mmHg 110 ± 13 117 ± 14 115 ± 11 128 ± 16 121 ± 15 66 ± 11b
MPAP, mmHg 15 ± 3 19 ± 3* 19 ± 3 22 ± 4 20 ± 4.0 31 ± 7b
CO, l/min 4.6 ± 1.4 4.9 ± 2.0 5.1 ± 1.5 5.2 ± 1.7 5.8 ± 2.3 5.5 ± 1.2
CVP, mmHg 9 ± 2 9 ± 1.0 10 ± 1 11 ± 2 11 ± 1 11 ± 2
PCWP, mmHg 7 ± 2 7 ± 2 7 ± 8 8 ± 2 9 ± 2 10 ± 2
SVR, dyn·s/cm5 1,843 ± 435 1,948 ± 525 1,734 ± 412 2,009 ± 703b 1,561 ± 553 870 ± 138b
PVR, dyn·s/cm5 145 ± 32 191 ± 52b 203 ± 36 255 ± 70b 138 ± 27 279 ± 138b
Hb, pH, blood gas tensions, and temperature, means ±
SD
Hba, g/dl 8.6 ± 1.3 9.0 ± 1.3 9.1 ± 1.0 11.1 ± 1.4
b 9.5 ± 0.6 9.6 ± 1.2
pHa 7.401 ±
0.072
7.369 ±
0.079
7.375 ±
0.051
7.346 ±
0.063
7.312 ±
0.089
7.217 ±
0.064b
PaO2, mmHg 161 ± 28 150 ± 40 150 ± 37 107 ± 39 114 ± 36 83 ± 23
b
PaCO2, mmHg 38 ± 13 38 ± 11 35 ± 7 34 ± 5 36 ± 7.0 38 ± 4
pHv 7.383 ±
0.074
7.360 ±
0.080
7.360 ±
0.056
7.346 ±
0.066
7.302 ±
0.087
7.210 ±
0.068b
PvO2, mmHg 50 ± 5 52 ± 6
b 52 ± 4 54 ± 4 56 ± 4 52 ± 7
PvCO2, mmHg 41 ± 14 41 ± 11 38 ± 8 35 ± 5 38 ± 6 40 ± 4
Temperature,°C 37.5 ± 0.6 37.5 ± 0.4 37.5 ± 0.3 37.3 ± 0.4 37.3 ± 0.4 37.1 ± 0.5
aHemodynamics and blood gas data in five sheep challenged with alternate exposure to H2S by ventilation of an extracorporeal membrane lung with 0 or 100
ppm H2S, 200 ppm H2S or 300 ppm H2S in air for 1-hour intervals each. ppm, parts per million; HR, heart rate; MAP, mean arterial pressure; MPAP, mean
pulmonary artery pressure; CO, cardiac output; CVP, central venous pressure; PCWP, pulmonary capillary wedge pressure; SVR, systemic vascular resistance; PVR,
pulmonary vascular resistance; Hba, arterial hemoglobin concentration; pHa, arterial pH; PaO2, arterial oxygen tension; PaCO2, arterial carbon dioxide tension; pHv,
mixed venous pH; PvO2, mixed venous oxygen tension; PvCO2, mixed venous carbon dioxide tension. All values are means ± SD and reflect the last 10 minutes of
each 1-hour period. n = 5. Values during H2S exposure were compared using Student’s t-test or the Wilcoxon signed-rank test with the preceding 0 ppm
baseline period, that is, first vs. second hour, third vs. fourth hour and fifth vs. sixth hour; bP ≤ 0.05.
Derwall et al. Critical Care 2011, 15:R51
http://ccforum.com/content/15/1/R51
Page 6 of 10
While H2S did not reduce VCO2 or VO2 in sheep in
the present study, Simon et al. [21] reported that con-
tinuous iv infusion of Na2S for 8 hours decreased the
core body temperature and VCO2 and VO2 levels in
pigs, suggesting that it is possible to reduce metabolic
rates in large mammals using a sulfide-based approach.
However, it is important to note that hypothermia itself
reduces the metabolic rate (Q10 effect). Therefore, in the
current study, body temperature was kept at 37°C
throughout the experiment to exclude any effects of
hypothermia on metabolism. Whether systemic adminis-
tration of Na2S reduces metabolic rates in large mam-
mals when normothermia is maintained remains to be
determined.
While our findings support the inability of H2S to
reduce metabolism in large mammals, these results dif-
fer from observations in mice in which H2S inhalation
markedly reduced metabolism [9,10,22]. Hydrogen sul-
fide may be one, but not the only, trigger for murine
metabolic depression. Indeed, hypoxia, anemia and
exposure to carbon monoxide have been reported to
reduce aerobic metabolism in mice [23-25], but not in
large mammals [26-28]. Of note is that mice are known
to have a much higher specific metabolic rate (approxi-
mately 168 kcal kg-1∙d-1 in a 30-g mouse) than sheep
(approximately 30 kcal kg-1∙d-1 in a 30-kg sheep) [29]. In
a previous study, we reported that H2S inhalation
reduced metabolism in awake, spontaneously breathing
mice by about 40% during normothermia, resulting in a
specific metabolic rate of no more than approximately
100 kcal∙kg-1∙d-1 [9]. In contrast, it has been reported
that H2S inhalation at 100 ppm failed to reduce CO2
production in normothermic mice that were anesthe-
tized and mechanically ventilated [30]. Interestingly, in
anesthetized mice studied by Baumgart et al. [30], the
baseline CO2 production rate before H2S inhalation was
approximately 50% less than that in awake mice studied
by Volpato et al. [9] in our laboratory. It is tempting to
speculate that the ability of H2S to reduce metabolism
depends on the specific metabolic rate of animals. H2S
may reduce metabolism when the baseline rate of meta-
bolism is high (for example, in awake mice), but not
when the metabolic rate is already depressed (for exam-
ple, in anesthetized mice or sheep).
Along these lines, it may be possible to reduce the
metabolic rate in larger mammals using H2S when
metabolism is increased. It has been reported that inha-
lation of 10 ppm H2S reduced oxygen consumption in
exercising healthy volunteers, presumably due to inhibi-
tion of aerobiosis in exercising muscle [31]. Inhibitory
effects of H2S in the presence of increased metabolism
in larger mammals warrants further study.
Our results show that administration of H2S via a cardi-
opulmonary bypass circulation can cause significant dose-
dependent pulmonary vasoconstriction. These observa-
tions are consistent with the pulmonary vasoconstrictor
effects of H2S in mammalian pulmonary vessels reported
by Olson et al. [32]. Although a potential role of H2S in
hypoxia sensing (hence hypoxic pulmonary vasoconstric-
tion) has been suggested [33], the mechanisms responsible
for the pulmonary vasoconstrictor effects of H2S remain
to be further elucidated.
Administration of H2S also tended to increase sys-
temic vascular resistance, but resulted in systemic vaso-
dilation after 30 minutes of ECML ventilation with 300
ppm H2S. This is consistent with previous reports
demonstrating that H2S can produce both vasoconstric-
tion and vasorelaxation in isolated rat aortic ring seg-
ments in an O2 concentration-dependent manner.
Koenitzer et al. [34] reported that H2S (5 to 80 μM
Na2S solution) causes vasorelaxation at O2 concentra-
tions reflecting the physiological oxygen tension in the
peripheral vasculature (O2 concentration, 40 μM). In
contrast, at high O2 concentrations (O2, 200 μM) under
which H2S is rapidly oxidized to sulfite, sulfate or thio-
sulfate, the administration of 5 to 100 μM Na2S causes
rat aortic vasoconstriction, and more than 200 μM Na2S
are required to cause vasorelaxation [34]. Along these
lines, the high oxygen tension observed in sheep on
ECML when ventilated with 100 and 200 ppm of H2S
may have contributed to the systemic vasoconstrictor
effects of H2S in the present study, whereas vasodilation
was only observed at the highest H2S concentration
(300 ppm). In addition, the O2 dependency of H2S-
mediated vasoconstriction may also explain why H2S
caused vasoconstriction in the pulmonary vasculature,
where O2 availability is consistently high.
While the toxicity of inhaling high levels of H2S is
well documented, the reported toxicity of H2S concen-
trations up to 500 ppm is almost exclusively limited to
mucosal membranes and the central nervous system
[35-37]. However, the cardiovascular toxicity of high
levels of inhaled H2S has not been reported. The
observed pulmonary hypertension and apparent changes
in systemic vascular tone in the current study may
therefore represent previously unrecognized toxic effects
of high levels of H2S in the circulation.
Despite the availability of various methods used to
quantify sulfide in biological fluids, it remains challen-
ging to measure circulating plasma concentrations of
H2S [38]. The methylene blue formation method
employed here measures “labile” total sulfide liberated
from sulfur compounds, but not free H2S in blood and
tissue. In the current study, considerable sulfide concen-
trations were detected in plasma obtained from blood
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efferent from the ECML, but not in the blood samples
from the femoral artery (sampled less than approxi-
mately 10 seconds after the blood left the ECML).
These observations suggest a rapid uptake of H2S into a
variety of sulfide pools once H2S has entered the blood
stream. Of note is that the measured plasma sulfide
level of 62 μM/l in the ECML efferent blood diffused
with 300 ppm H2S was only about 3% of the expected
sulfide level of approximately 2,000 μM/l assuming a
blood volume of 70 ml/kg. These results are consistent
with a recent report that circulating free sulfide levels
are almost undetectably low at baseline and that exo-
genous sulfide is also rapidly removed from the circulat-
ing plasma [39]. Nonetheless, the pronounced
vasoreactivity induced by H2S administration observed
in the current study suggests that H2S (and/or its active
metabolites) is transported to the periphery and exerts
biological effects. The fate of exogenously administered
H2S remains to be determined in future studies using
more sensitive methods.
Although the results of the current study do not sug-
gest that H2S can be used to reduce metabolic rate in
larger mammals, these results do not refute the potential
organ protective effects of H2S reported elsewhere. The
dose of 134 μM/kg/h that was applied here is almost 20
times higher than the effective dose of Na2S reported to
improve survival in mice after cardiac arrest (0.55 μg/g,
that is, approximately 7 μM/kg) [12]. Studies by others
have also shown that administration of H2S donors in a
similarly low dose range were able to protect organs
from ischemic insults in rodents and pigs without redu-
cing metabolic rate or body temperature [14,40]. Taken
together, it is conceivable that organ-protective effects
and metabolic effects of H2S may be mediated via two
different mechanisms and/or at different concentrations.
Limitations
Measuring oxygen consumption is a valuable tool to
assess metabolic rate. However, quantification of oxygen
consumption in the setting of ECML requires serial
simultaneous determinations of oxygen content in arter-
ial and mixed venous blood as well as blood afferent
and efferent to the ECML [41]. Small measuring inac-
curacies in the parameters needed to calculate oxygen
content (hemoglobin, oxygen saturation and tension)
result in an exponential increase in the overall inaccu-
racy of the calculated VO2 value. In contrast, measuring
CO2 production requires only CO2 quantification in the
exhaled gas of both the natural and the artificial lung
because virtually no CO2 is present in the inhaled gas
mixture, which is a major advantage to simplifying the
setup and avoiding exponential error. Therefore, VCO2
may be the more reliable index for estimating the meta-
bolic rate in this study.
The present study was designed to detect a reduction
in metabolic rate of about 30% in sheep. On the basis of
the variance of metabolic rates determined in pilot
experiments in sheep, a sample size of 12 sheep was cal-
culated to find a 30% reduction in metabolic rate (80%
power and 5% probability of error). An interim analysis
of this study (n = 5) did not substantiate a significant
change or trend in VCO2 (Figure 3) and precluded
additional experiments.
Conclusions
The results of the present study demonstrate that venti-
lating an ECML with up to 300 ppm H2S in partial car-
diopulmonary bypass circulation does not reduce CO2
production or O2 consumption in anesthetized sheep.
Our results show that diffusion of up to 300 ppm H2S
into blood via a membrane lung can cause dose-depen-
dent pulmonary vasoconstriction, hypoxemia and cata-
strophic systemic vasodilation. These observations do
not support the hypothesis that administration of a high
concentration of H2S reduces metabolism in anesthe-
tized large mammals. Whether the administration of
H2S inhibits metabolism in large mammals when meta-
bolic rate is increased (for example, systemic inflamma-
tion or exercise) remains to be determined.
Key messages
• High concentrations of H2S administered via ECML
ventilation do not alter CO2 production in sheep on
partial cardiopulmonary bypass perfusion.
• In this setting, H2S poses the risk of pulmonary vaso-
constriction, hypoxemia and systemic vasodilation.
• Therefore, administration of high concentrations of
H2S via membrane lung may not be useful for redu-
cing oxidative metabolism in large mammals.
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